Sugi Predict

Sugi Predict / Compounds / SCHEMBL23338593

SCHEMBL23338593

SCHEMBL23338593

CO[C@@H](C)c1ncc(N2CCN(C(=O)OCc3ccccc3)CC2)cc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.49
▸ NR1H3 Q13133 1/20 0.49
▸ TMEM97 Q5BJF2 10/20 0.41
▸ SIGMAR1 Q99720 10/20 0.41
▸ HRH1 P35367 2/20 0.41
▸ HRH3 Q9Y5N1 2/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ ADRA2A P08913 1/20 0.41
▸ ADRA2B P18089 1/20 0.41
▸ ADRA2C P18825 1/20 0.41
▸ DRD1 P21728 1/20 0.41
▸ HRH2 P25021 1/20 0.41
▸ HTR1B P28222 1/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ HTR1E P28566 1/20 0.41
▸ SLC6A4 P31645 1/20 0.41
▸ HTR2B P41595 1/20 0.41
▸ HDAC1 Q13547 2/20 0.40
▸ HDAC3 O15379 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27143761 1.00 NR1H2 (0.49) NR1H2NR1H3TMEM97SIGMAR1HRH1
SCHEMBL25889395 0.92 NR1H2 (0.51) NR1H2NR1H3TMEM97SIGMAR1HRH1
SCHEMBL25249577 0.85 NR1H2 (0.48) NR1H2NR1H3TMEM97SIGMAR1HRH1
SCHEMBL23295414 0.85 NR1H2 (0.33) NR1H2NR1H3HRH3MEN1KMT2A
SCHEMBL29412391 0.85 NR1H2 (0.33) NR1H2NR1H3HRH3MEN1KMT2A
SCHEMBL23295412 0.85 NR1H2 (0.33) NR1H2NR1H3HRH3MEN1KMT2A
SCHEMBL31228353 0.83 TMEM97 (0.47) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL23296608 0.83 TMEM97 (0.47) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL23296610 0.83 TMEM97 (0.47) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL23295344 0.83 MAPT (0.40) MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624053-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2026-05-12 — — US disclosed
EP-4558507-B1 MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN LA ROCHE (CH) 2026-04-29 — — EP disclosed
EP-4720072-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-04-08 — — EP disclosed
US-20260078133-A1 RAS INHIBITORS Revolution Medicines, Inc. 2026-03-19 — — US disclosed
US-20260070930-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2026-03-12 — — US disclosed
EP-4696316-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-18 — — EP disclosed
US-20260042740-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-12 — — US disclosed
EP-4054719-B1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-11 — — EP disclosed
EP-4688789-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 — — EP disclosed
US-20250388608-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-12-25 — — US disclosed
US-11566007-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-01-31 — — US disclosed
US-20220396589-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2022-12-15 — — US disclosed
WO-2022251292-A1 METHODS FOR INHIBITING RAS Revolution Medicines, Inc. (US) 2022-12-01 — — WO disclosed
WO-2022235864-A1 RAS INHIBITORS Revolution Medicines, Inc. (US) 2022-11-10 — — WO disclosed
EP-4054719-A1 RAS INHIBITORS Revolution Medicines, Inc. (US) 2022-09-14 — — EP disclosed
EP-4055028-A1 RAS INHIBITORS Revolution Medicines, Inc. (US) 2022-09-14 — — EP disclosed
US-20220105185-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2022-04-07 — — US disclosed
WO-2022060836-A1 INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER Revolution Medicines, Inc. (US) 2022-03-24 — — WO disclosed
WO-2022060583-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. (US) 2022-03-24 — — WO disclosed
US-20210130369-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070930-A1 RAS INHIBITORS KRAS, NRAS, RIN1 NR1H2 255/4885NR1H3 466/4885TMEM97 1855/4885
US-20220396589-A1 RAS INHIBITORS KRAS, NRAS, HRAS NR1H2 3034/4885NR1H3 3057/4885TMEM97 3700/4885
US-20260078133-A1 RAS INHIBITORS KRAS, NRAS, HRAS NR1H2 2623/4885NR1H3 2806/4885TMEM97 1470/4885
US-20260042740-A1 RAS INHIBITORS KRAS, NRAS, HRAS NR1H2 2468/4885NR1H3 2388/4885TMEM97 2850/4885
US-12624053-B2 Ras inhibitors KRAS, NRAS, HMGCR NR1H2 221/4885NR1H3 339/4885TMEM97 2659/4885
US-11566007-B2 Ras inhibitors KRAS, NRAS, HRAS NR1H2 3359/4885NR1H3 3408/4885TMEM97 3495/4885
US-20220105185-A1 RAS INHIBITORS KRAS, NRAS, HRAS NR1H2 3359/4885NR1H3 3408/4885TMEM97 3495/4885
US-20250388608-A1 RAS INHIBITORS KRAS, NRAS, HMGCR NR1H2 221/4885NR1H3 339/4885TMEM97 2659/4885
US-20210130369-A1 RAS INHIBITORS KRAS, NRAS, HRAS NR1H2 3359/4885NR1H3 3408/4885TMEM97 3495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.